# Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

> **NCT06114407** · PHASE2 · UNKNOWN · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 184 (estimated)

## Conditions studied

- Spondyloarthritis, Axial

## Interventions

- **DRUG:** Baricitinib 2mg
- **DRUG:** Tofacitinib 5 mg

## Key facts

- **NCT ID:** NCT06114407
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-30
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114407, "Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06114407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*